$Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer$

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer

Targeted therapy has brought revolutionary breakthroughs for radioiodine-refractory differentiated thyroid cancer. New targeted drugs have prolonged the survival of patients with advanced differentiated thyroid cancer. Multiple tyrosine kinase inhibitors, represented by sorafenib and lenvatinib, hav...

Full description

Bibliographic Details
Main Authors:	TENG Lisong, XU Zehang, WANG Weibin
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2023-05-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	radioiodine-refractory differentiated thyroid cancer targeted therapy tyrosine kinase inhibitor
Online Access:	http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0009

Similar Items

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
by: Wei Du, et al.
Published: (2022-02-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
by: Genpeng Li, et al.
Published: (2018-11-01)

Progress in Re-differentiating Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: ZHANG Yaqi, et al.
Published: (2022-10-01)

Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
by: Xiaoyu Ji, et al.
Published: (2022-08-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
by: Jaume Capdevila, et al.
Published: (2023-08-01)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
by: Costanza Chiapponi, et al.
Published: (2021-12-01)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
by: Javier Martínez‐Trufero
Published: (2022-10-01)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
by: Chao Meng, et al.
Published: (2023-02-01)

Recurrent Differentiated Thyroid Cancer: The Current Treatment Options
by: Andrés Coca-Pelaz, et al.
Published: (2023-05-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
by: Chiaki Suzuki, et al.
Published: (2021-07-01)

APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020-06-01)

Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer
by: Christos Cortas, et al.
Published: (2023-12-01)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
by: Angelica Schmidt, et al.
Published: (2017-02-01)

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
by: Sarah Hamidi, et al.
Published: (2023-06-01)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
by: Swayamjeet Satapathy, et al.
Published: (2022-07-01)

Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
by: Mohamed Aashiq, et al.
Published: (2019-09-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
by: Maaike Dotinga, et al.
Published: (2022-12-01)

Selective use of sorafenib in the treatment of thyroid cancer
by: Pitoia F, et al.
Published: (2016-03-01)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
by: Xian Qiu, et al.
Published: (2023-01-01)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
by: Liu H, et al.
Published: (2023-02-01)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
by: Genpeng Li, et al.
Published: (2022-12-01)

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma
by: LIU Wei
Published: (2023-11-01)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
by: Petra Petranović Ovčariček, et al.
Published: (2023-08-01)

Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)
by: WEN Qiang, et al.
Published: (2023-11-01)

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
by: Tremblay G, et al.
Published: (2016-06-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
by: June-Key Chung, et al.
Published: (2014-09-01)

Potential of the drug-regulation iodide uptake in patients for prevention of radioiodine-refractory papillary thyroid cancer
by: Dmitriy Kirillovich Fomin, et al.
Published: (2014-11-01)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
by: Elena Navarro‐Gonzalez
Published: (2022-10-01)

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
by: Teresa Alonso‐Gordoa
Published: (2022-10-01)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
by: Aleksandra Kukulska, et al.
Published: (2020-08-01)

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
by: Freba Ahmaddy, et al.
Published: (2021-01-01)

Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
by: Mariya Alekseevna Karalkina, et al.
Published: (2015-07-01)

Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database
by: Wallace Klein Schwengber, et al.
Published: (2020-10-01)